Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Dermatophytic Onychomycosis Therapeutics (DOT) Market Research Report 2024
Market growth is primarily driven by factors such as increase in the prevalence of fungal toe nail infections in the U.S. and Canada, and rising per capita healthcare expenditure across the globe. Easy application of nail paints is also expected to drive demand for dermatophytic onychomycosis drugs. However, adverse effects associated with anti-fungal drugs and lack of awareness about dermatophytic onychomycosis in Asia Pacific, Middle East and Africa, and Latin America are expected to impede growth of the global dermatophytic onychomycosis therapeutics market.
According to Mr Accuracy reports’s new survey, global Dermatophytic Onychomycosis Therapeutics (DOT) market is projected to reach US$ 6835.3 million in 2034, increasing from US$ 3394.3 million in 2022, with the CAGR of 10.3% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Dermatophytic Onychomycosis Therapeutics (DOT) market research.
The global dermatophytic onychomycosis therapeutics market is anticipated to expand at a healthy CAGR during the forecast period. By product type, the market is segmented into Nail paint and tablet, which is again sub-divided into prescription (Rx) and over-the-counter (OTC) sub segments. The nail paint segment is expected to contribute a maximum share to the global dermatophytic onychomycosis therapeutics market. By treatment, the market is segmented into topical and oral therapy. Among these, the topical segment is anticipated to be dominant throughout the forecast period and projected to account for about 70% share of the total global dermatophytic onychomycosis market revenue by 2025.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dermatophytic Onychomycosis Therapeutics (DOT) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Galderma
Bausch Health
Novartis
Pfizer
Janssen
Segment by Type
Topical
Oral Therapy
Hospitals
Dermatology And Podiatry Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Dermatophytic Onychomycosis Therapeutics (DOT) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Dermatophytic Onychomycosis Therapeutics (DOT) market is projected to reach US$ 6835.3 million in 2034, increasing from US$ 3394.3 million in 2022, with the CAGR of 10.3% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Dermatophytic Onychomycosis Therapeutics (DOT) market research.
The global dermatophytic onychomycosis therapeutics market is anticipated to expand at a healthy CAGR during the forecast period. By product type, the market is segmented into Nail paint and tablet, which is again sub-divided into prescription (Rx) and over-the-counter (OTC) sub segments. The nail paint segment is expected to contribute a maximum share to the global dermatophytic onychomycosis therapeutics market. By treatment, the market is segmented into topical and oral therapy. Among these, the topical segment is anticipated to be dominant throughout the forecast period and projected to account for about 70% share of the total global dermatophytic onychomycosis market revenue by 2025.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Dermatophytic Onychomycosis Therapeutics (DOT) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Galderma
Bausch Health
Novartis
Pfizer
Janssen
Segment by Type
Topical
Oral Therapy
Segment by Application
Hospitals
Dermatology And Podiatry Clinics
Independent Pharmacies
Mail Order Pharmacies
Drug Stores
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Dermatophytic Onychomycosis Therapeutics (DOT) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices